Search Within

David Henry Aggen

Formats
  1. Meeting Abstract (45)
  2. Journal Article (10)
  3. Editorial (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Department of Medicine (60)
  2. Genitourinary Oncology Service (60)
  3. Hematologic Malignancies, Division of (60)
  4. Solid Tumor Oncology Division (60)
  5. Weinberg Fellows (42)
  6. Graduate Medical Education (38)

More Groups

People
  1. Jonathan Rosenberg (31)
  2. Gopakumar Iyer (29)
  3. Dean Bajorin (26)
  4. Samuel Funt (26)
  5. Min Yuen Teo (25)
  6. Chung-Han Lee (22)

More People

Years
  1. 2025 (9)
  2. 2024 (17)
  3. 2023 (12)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (4)

More Years

Publications
  1. Journal of Clinical Oncology (37)
  2. Clinical Cancer Research (4)
  3. Cancer Research (3)
  4. European Urology (3)
  5. Journal for ImmunoTherapy of Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (38)
  2. American Association for Cancer Research (7)
  3. Biomed Central Ltd (3)
  4. Elsevier Science, Inc. (3)
  5. Elsevier Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (60)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Lenis, A. T.; Chen, Z.; Al-Ahmadie, H. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience
    Meeting Abstract

    Guercio, B. J.; Gandhi, J.; Teo, M. Y.; Lattanzi, M.; Funt, S. A.; Aggen, D. H.; Chen, Y. B.; Fine, S.; Pietzak, E. J.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma
    Meeting Abstract

    Teo, M. Y.; Ratna, N.; Regazzi, A. M.; Zimmerman, D. E.; McHugh, D. J.; Laccetti, A. L.; Xiao, H.; Lee, C. H.; Aggen, D. H.; Funt, S. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Considerations for treatment duration in responders to immune checkpoint inhibitors
    Review

    Marron, T. U.; Ryan, A. E.; Reddy, S. M.; Kaczanowska, S.; Younis, R. H.; Thakkar, D.; Zhang, J.; Bartkowiak, T.; Howard, R.; Anderson, K. G.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: Multidimensional analyses
    Journal Article

    Aggen, D. H.; Ager, C. R.; Obradovic, A. Z.; Chowdhury, N.; Ghasemzadeh, A.; Mao, W.; Chaimowitz, M. G.; Lopez-Bujanda, Z. A.; Spina, C. S.; Hawley, J. E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Tumor-specific cell populations in clear cell renal carcinoma associated with clinical outcome identified using single-cell protein activity inference
    Meeting Abstract

    Obradovic, A.; Showdhury, N.; Ager, C.; Wang, V.; Vlahos, L.; Guo, X. V.; Aggen, D. H.; McKiernan, J.; Califano, A.; Drake, C. G.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    Teo, M. Y.; Whiting, K.; Mota, J. M.; Li, H.; Regazzi, A. M.; Solit, D. B.; Aggen, D. H.; Lee, C. H.; Funt, S. A.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Microsatellite instability (MSI-H) in metastatic urothelial carcinoma (mUC): A biomarker of divergent responses to systemic therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Al-Ahmadie, H.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Solit, D. B.; Ratna, N.; Regazzi, A. M.; Hechtman, J. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Human prostate cancer immune phenotypes after androgen deprivation therapy
    Meeting Abstract

    Dallos, M.; Obradovic, A.; Chowdhury, N.; Bujanda, Z. L.; Aggen, D. H.; Hawley, J.; Rathkopf, D. E.; Drake, C. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save